See every side of every news story
Get Started
SubscribeLogin
Social Media
Baseball
Celtic
Natural Disasters
Donald Trump
Champions League
Israel-Hamas Conflict
Tariffs
Immigration
Trade
Tennis
IPL
Published • loading... • Updated

Wugen Announces Dosing of First Patients in Pivotal Trial of Off-the-Shelf, Allogeneic, ...

Summary by Hastings Tribune
- Previously reported Phase 1/2 data on WU-CART-007 demonstrated clinically manageable safety and evidence of anti-leukemic activity with an overall response rate of 91% and composite complete remission rate of 73% in heavily pretreated patients with R/R T-ALL/LBL

1 Articles

All
Left
Center
1
Right
Hastings TribuneHastings Tribune
Center

Wugen Announces Dosing of First Patients in Pivotal Trial of Off-the-Shelf, Allogeneic, ...

- Previously reported Phase 1/2 data on WU-CART-007 demonstrated clinically manageable safety and evidence of anti-leukemic activity with an overall response rate of 91% and composite complete remission rate of 73% in heavily pretreated patients with R/R T-ALL/LBL

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Hastings Tribune broke the news in on Thursday, March 20, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Hastings, Nebraska

Hastings, Nebraska

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.

News
For You
SearchBlindspotLocal